Clinical Observation of Trantuzumab Combined with Preoperative Adjuvant Chemotherapy in the Treatment of Her-2 Positive Breast Cancer
10.6039/j.issn.1001-0408.2015.29.25
- VernacularTitle:曲妥珠单抗联合术前辅助化疗用于Her-2阳性乳腺癌的临床观察
- Author:
Xuezhen YING
;
Chunjun HUANG
- Publication Type:Journal Article
- Keywords:
Trastuzumab;
Chemotherapy;
Her-2 positive breast cancer;
Infiltration and metastasis;
Prognosis
- From:
China Pharmacy
2015;(29):4104-4106,4107
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To observe the effect of trantuzumab combined with preoperative adjuvant chemotherapy in the treat-ment of human epidermal growth factor receptors 2 (Her-2) positive breast cancer,and to investigate its clinical value. METH-ODS:80 patients with Her-2 positive breast cancer were selected and randomly divided into observation group and control group, with 40 cases in each group. The control group received routine preoperative adjuvant chemotherapy+modified radical mastectomy for Her-2 positive breast cancer;observation group was additionally treated with trastuzumab intravenously before operation,initial dose of 4 mg/kg,followed by 2 mg/kg,once a week,for consecutive 3 weeks,on the basis of control group. The effects of two regimen on the expression of HER-2,CD-34,MGA,E-cadherin and GCDFE-15 in Her 2 positive breast cancer focus were com-pared between 2 groups. ADR and follow-up survey were recorded. RESULTS:Compared with before chemotherapy,the expres-sion of HER-2(+)in observation group increased significantly,while that of HER-2(+ + +)decreased significantly;MGA posi-tive rate and GCDFP-15 positive rate decreased significantly while E-cadherin positive rate increased significantly;MDV of CD34 expression decreased significantly,with statistical significance(P<0.05 or P<0.01). Relapse rate and distance transport rate of ob-servation group were significantly lower than those of control group,with statistical significance(P<0.05). There was no statisti-cal significance in the incidence of ADR between 2 groups(P>0.05). CONCLUSIONS:Trastuzumab combined with preoperative adjuvant chemotherapy have good clinical efficacy and safety,and it can effectively reduce related indicator of Her-2 positive breast cancer focus. So it has positive significance in reducing recurrence and metastasis of breast cancer.
